RPT-European shares end higher; drugs, commods gain

Thu May 15, 2008 4:39pm BST
 
Email | Print | | Single Page
[-] Text [+]

(repeats to attach to alerts)

LONDON, May 15 (Reuters) - European shares ended higher on Thursday as gains in drugs and commodity stocks offset the impact of banks, which weakened after Barclays (BARC.L: Quote, Profile, Research) unveiled writedowns and left the door open for a rights issue.

The pan-European FTSEurofirst 300 index ended unofficially 0.3 percent higher at 1,358.74 points, its third day of modest gains so far this week.

The index has now gained 1.7 percent this month, building on a 6-percent gain in April, giving investors respite from a sharp slide that started almost a year ago due to credit market problems.

Roche Holding (ROG.VX: Quote, Profile, Research) rose 2.5 percent and Novartis (NOVN.VX: Quote, Profile, Research) gained 2 percent on hopes for key cancer drug trials due to be presented at a researchers' meeting at the end of the month. Much of the information wil be available from Friday.

BT Group jumped 5.4 percent after posting strong fourth-quarter results, while Deutsche Postbank (DPBGn.DE: Quote, Profile, Research) rose 3 percent to top German gainers on talk of takeover interest from insurer Allianz (ALVG.DE: Quote, Profile, Research). Allianz and Postbank's owner Deutsche Post (DPWGn.DE: Quote, Profile, Research) both declined to comment.

Vivendi (VIV.PA: Quote, Profile, Research), Europe's largest entertainment group, jumped 5.2 percent after posting a smaller-than-expected drop in first-quarter operating profit late on Wednesday.

Miners and oil stocks tracked copper and crude prices higher.

Anglo American (AAL.L: Quote, Profile, Research), Rio Tinto (RIO.L: Quote, Profile, Research) and BHP Billiton (BLT.L: Quote, Profile, Research) all gained more than 1.7 percent while BP (BP.L: Quote, Profile, Research) tacked on 0.6 percent.  Continued...

 

Editor's Choice

Photo

A selection of our best photos from the past 24 hours.  View Slideshow 

Most Popular on Reuters UK